Patents by Inventor Barry G. W. Arnason
Barry G. W. Arnason has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210188975Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc?R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc?R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc?R in autoimmune disorders.Type: ApplicationFiled: June 28, 2020Publication date: June 24, 2021Applicant: Iterative Therapeutics, Inc.Inventors: Barry G.W. Arnason, Mark A. Jensen, David M. White
-
Publication number: 20190055310Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc?R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc?R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc?R in autoimmune disorders.Type: ApplicationFiled: March 9, 2018Publication date: February 21, 2019Applicant: Iterative Therapeutics, Inc.Inventors: Barry G.W. Arnason, Mark A. Jensen, David M. White
-
Publication number: 20160194395Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc?R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc?R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc?R in autoimmune disorders.Type: ApplicationFiled: August 6, 2015Publication date: July 7, 2016Applicant: ITERATIVE THERAPEUTICS, INC.Inventors: Barry G.W. Arnason, Mark A. Jensen, David M. White
-
Patent number: 9127063Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc?R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc?R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc?R in autoimmune disorders.Type: GrantFiled: March 10, 2013Date of Patent: September 8, 2015Assignee: Iterative Therapeutics, Inc.Inventors: Barry G. W. Arnason, Mark A. Jensen, David M. White
-
Patent number: 8986698Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc?R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc?R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc?R in autoimmune disorders.Type: GrantFiled: February 12, 2011Date of Patent: March 24, 2015Assignee: Iterative Therapeutics, Inc.Inventors: Barry G. W. Arnason, Mark A. Jensen, David M. White
-
Patent number: 8163289Abstract: The present invention concerns inventive polypeptides. The present invention also concerns compositions and vaccines comprising the inventive polypeptides. In other embodiments of the invention, the inventive polypeptides are provided to a subject, used to vaccinate, or used to induce immunity. Other embodiments include methods for making the inventive polypeptides and nucleic acids used to encode the inventive polypeptides.Type: GrantFiled: March 6, 2008Date of Patent: April 24, 2012Assignee: Iterative Therapeutics, Inc.Inventors: Barry G. W. Arnason, Mark A. Jensen, David M. White
-
Publication number: 20110195067Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc?R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc?R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc?R in autoimmune disorders.Type: ApplicationFiled: February 12, 2011Publication date: August 11, 2011Applicant: Iterative Therapeutics, Inc.Inventors: Barry G. W. Arnason, Mark A. Jensen, David M. White
-
Patent number: 7897729Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc?R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc?R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fission proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc?R in autoimmune disorders.Type: GrantFiled: September 18, 2008Date of Patent: March 1, 2011Assignee: Iterative Therapeutics, Inc.Inventors: Barry G. W. Arnason, Mark A. Jensen, David M. White
-
Publication number: 20090117133Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc?R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc?R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fission proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc?R in autoimmune disorders.Type: ApplicationFiled: September 18, 2008Publication date: May 7, 2009Applicant: ITERATIVE THERAPEUTICS, INC.Inventors: Barry G.W. Arnason, Mark A. Jensen, David M. White
-
Patent number: 7511121Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc?R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc?R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc?R in autoimmune disorders.Type: GrantFiled: March 11, 2002Date of Patent: March 31, 2009Inventors: Barry G. W. Arnason, Mark A. Jensen, David M. White
-
Publication number: 20080292704Abstract: The present invention concerns inventive polypeptides. The present invention also concerns compositions and vaccines comprising the inventive polypeptides. In other embodiments of the invention, the inventive polypeptides are provided to a subject, used to vaccinate, or used to induce immunity. Other embodiments include methods for making the inventive polypeptides and nucleic acids used to encode the inventive polypeptides.Type: ApplicationFiled: March 6, 2008Publication date: November 27, 2008Applicant: ITERATIVE THERAPEUTICS, INC.Inventors: Barry G.W. Arnason, Mark A. Jensen, David M. White
-
Publication number: 20030161826Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc&ggr;R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc&ggr;R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc&ggr;R in autoimmune disorders.Type: ApplicationFiled: March 11, 2002Publication date: August 28, 2003Applicant: The University of ChicagoInventors: Barry G. W. Arnason, Mark A. Jensen, David M. White
-
Patent number: 5264459Abstract: The present invention discloses improved methods for the treatment of autoimmune diseases using .beta.-adrenergic agonists, and particularly, .beta..sub.2 -adrenergic agonists. The treatment of animals with either EAE or EAN using the .beta..sub.2 -adrenergic agonist terbutaline significantly suppressed clinical disease. A Phase I safety treatment trial with terbutaline was conducted in MS patients. Twenty-four patients were treated for 4 weeks. No obvious side effects were observed. At 4 weeks, 15 of the 24 patients improved on neurologic rating scale and 17 patients reported subjective improvement. Treatment of rats with EAMG, an animal model of tThe government may own rights in the present invention pursuant to NIH grants 2 RO1 NS18413-07A1 and PO1NS-24575-03.Type: GrantFiled: July 13, 1992Date of Patent: November 23, 1993Assignee: ARCH Development CorporationInventors: Ewa E. Chelmicka-Schorr, Barry G. W. Arnason, Anthony T. Reder, Louis Cohen